Selegiline hydrochloride is a selective, irreversible (covalent) inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. References: Zhang YL, Li YP. [Simultaneous determination of scopolamine hydrobromide, atropine sulfate, ephedrine hydrochloride and pseudoephedrine hydrochloride in Zhichuanling oral liquid with HPLC]. Zhongguo Zhong Yao Za Zhi. 2013 Oct;38(19):3291-4. Chinese. PubMed PMID: 24422394.

纯度：≥98%

CAS：14611-52-0